CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

March 4th, 2015

FDA: Testosterone Therapy May Pose Cardiovascular Risks

Men who use testosterone products to treat low testosterone may be at increased risk for myocardial infarction, stroke, and death, the FDA cautioned on Tuesday. The agency is requiring a label change to warn of these risks and to clarify the approved uses for such products.

The action — which updates a drug safety communication from January 2014 — is based on studies that demonstrated a potential link between testosterone therapy and cardiovascular risks, and on contributions from an FDA advisory panel.

The FDA emphasized that testosterone products are approved only for treating low testosterone caused by medical conditions such as disorders of the brain, pituitary gland, and testicles. Benefits for age-related low testosterone haven’t been demonstrated.

– See more at: http://www.jwatch.org/fw109934/2015/03/04/fda-testosterone-therapy-may-pose-cardiovascular-risks#sthash.46ZoNISE.dpuf

Categories: General


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.